ReviewClinical reviews in allergy & immunology
Recovery from bronchoconstriction and bronchodilator tolerance.
Review in Clinical reviews in allergy & immunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.The Cochrane database of systematic reviews · 2021Pooled it
- Inhaled steroids with and without regular salmeterol for asthma: serious adverse events.The Cochrane database of systematic reviews · 2018Pooled it
- Regular treatment with formoterol for chronic asthma: serious adverse events.The Cochrane database of systematic reviews · 2012Pooled it
- Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events.The Cochrane database of systematic reviews · 2012Pooled it
- Regular treatment with salmeterol for chronic asthma: serious adverse events.The Cochrane database of systematic reviews · 2008Pooled it
- Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide.American journal of respiratory and critical care medicine · 2013Trial
- Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials.Respiratory research · 2007Trial
- Medication Adherence in Medicare-Enrolled Older Adults with Chronic Obstructive Pulmonary Disease before and during the COVID-19 Pandemic.Journal of clinical medicine · 2022Article
- Transforming Growth Factor-β1 Decreases βAmerican journal of respiratory cell and molecular biology · 2019Article
- Antispasmodic Activity of Prenylated Phenolic Compounds from the Root Bark ofMolecules (Basel, Switzerland) · 2019Article
- Effects of standardized extracts of Lamium album and Urtica dioica on rat tracheal smooth muscle contraction.Journal of pharmacopuncture · 2018Article
- Exercise-Induced Bronchospasm and Allergy.Frontiers in pediatrics · 2017Review
- Targeting G protein coupled receptor-related pathways as emerging molecular therapies.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2015Review
- Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma?NPJ primary care respiratory medicine · 2014Article
- Pediatric exercise-induced bronchoconstriction: contemporary developments in epidemiology, pathogenesis, presentation, diagnosis, and therapy.Current allergy and asthma reports · 2013Review
- Airway smooth muscle in the pathophysiology and treatment of asthma.Journal of applied physiology (Bethesda, Md. : 1985) · 2013Review
- A novel EST-derived RNAi screen reveals a critical role for farnesyl diphosphate synthase in β2-adrenergic receptor internalization and down-regulation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2012Article
- Airway hyperresponsiveness in asthma: mechanisms, clinical significance, and treatment.Frontiers in physiology · 2012Article
- Assessment of bronchodilator responsiveness after methacholine-induced bronchoconstriction.Allergy, asthma & immunology research · 2011Article
- Assessment of bronchodilator responsiveness following methacholine-induced bronchoconstriction in children with asthma.Allergy, asthma & immunology research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Until recently, researchers believed that tolerance or tachyphylaxis to the bronchodilator effects of beta-agonists did not occur. However, recent studies examining the recovery from bronchoconstriction have clearly shown that an impaired response to beta-agonists occurs in patients who have been using regular beta-agonist treatment. This tolerance develops with both long- and short-acting beta-agonists and is not affected by treatment with inhaled steroids. It develops rapidly, reaching a maximum within 1 wk of starting beta-agonists, and has been demonstrated after methacholine, hypertonic saline, mannitol, and exercise-induced bronchoconstriction. The observed reduction in the bronchodilator response is proportional to the severity of bronchoconstriction. Therefore, although individuals with stable asthma show little evidence of tolerance, those with severe bronchospasm have a markedly reduced bronchodilator response to beta-agonists. Almost all asthmatics show evidence of tolerance when tested in the setting of bronchoconstriction, although the extent of this tolerance varies. The reasons for this interindividual variation are not understood. Bronchodilator tolerance is difficult to study in the clinical setting because nearly every patient has used multiple doses of beta-agonist before seeking medical attention. However, there is compelling evidence that the response to rescue beta-agonist treatment is reduced in those who use regular long- or short-acting beta-agonists. The extent to which this phenomenon contributes to asthma morbidity and mortality remains to be determined.
Indexed as
Identifiers
17085792What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.